Alex Rodriguez TRT Comparison to Similar Public Figures

Alex Rodriguez's Documented Testosterone History

Alex Rodriguez's connection to testosterone is among the most scrutinized in sports history. His case provides a reference point for understanding how testosterone use in public figures gets disclosed, denied, and eventually confirmed.

The 2009 Admission

In February 2009, Rodriguez confirmed in an interview with ESPN's Peter Gammons that he had used banned substances between 2001 and 2003 while playing for the Texas Rangers. He stated: "When I arrived in Texas in 2001, I felt an enormous amount of pressure. I needed to perform, and I did take a banned substance." He identified the substances as testosterone and Primobolan (methenolone), both anabolic-androgenic steroids listed on the World Anti-Doping Agency's prohibited list [1].

This admission came after a Sports Illustrated report revealed he had tested positive during MLB's anonymous 2003 survey testing. That survey was intended to determine whether mandatory testing was necessary. Of the 1,198 players tested, 104 (roughly 8.7%) tested positive [2].

The Biogenesis Suspension

Rodriguez's second and more consequential entanglement with testosterone came through the Biogenesis anti-aging clinic in Coral Gables, Florida. Clinic founder Anthony Bosch provided performance-enhancing substances, including testosterone cream and injectable testosterone, to multiple professional athletes [3].

MLB suspended Rodriguez for 211 games in August 2013. An arbitrator reduced the penalty to 162 games (the entire 2014 season) plus the 2014 postseason. Rodriguez did not test positive during this period. The suspension relied on evidence from clinic records, witness testimony, and text messages rather than a failed drug test [3].

The Biogenesis case highlighted a gap in anti-doping enforcement: athletes could use testosterone preparations obtained outside standard testing windows and avoid detection through careful timing. Rodriguez's protocol reportedly included topical testosterone creams, which have shorter detection windows than injectable formulations [4].

How Rodriguez Compares to Other Athletes Linked to Testosterone

Several professional athletes have faced scrutiny over testosterone use. The circumstances, transparency, and outcomes vary widely.

Manny Ramirez: Repeat Violations

Manny Ramirez, Rodriguez's contemporary in MLB, received a 50-game suspension in 2009 after testing positive for human chorionic gonadotropin (hCG), a hormone sometimes used alongside testosterone to maintain testicular function during or after steroid cycles [5]. Ramirez faced a second violation in 2011, which carried a 100-game suspension. He initially retired rather than serve it.

Unlike Rodriguez, Ramirez never gave a detailed public accounting of what he used or why. The contrast is notable: Rodriguez's case involved extensive public testimony and legal proceedings, while Ramirez's remained comparatively opaque.

Vitor Belfort: The TRT Exemption Era in UFC

Mixed martial arts offers the most direct comparison for legitimate TRT use in competition. From roughly 2010 to 2014, several UFC fighters obtained therapeutic use exemptions (TUEs) for testosterone replacement therapy. Vitor Belfort was the most prominent [6].

Belfort openly acknowledged using TRT under medical supervision, arguing that prior steroid use had damaged his endogenous testosterone production. His testosterone-to-epitestosterone (T/E) ratio was monitored by athletic commissions. When the UFC banned TRT exemptions in February 2014, Belfort's performance declined noticeably. He went from finishing five of six opponents in 2013 to 2014 to a more modest record in subsequent years.

The Belfort case illustrates a clinical reality documented in the Endocrine Society's 2018 guidelines: prior anabolic steroid use can cause persistent hypogonadism through hypothalamic-pituitary-gonadal axis suppression, creating a genuine medical need for testosterone replacement [7]. Whether that need should permit competitive advantage is a separate ethical question.

Anderson Silva: Post-Career Testing

Anderson Silva, widely considered one of the greatest MMA fighters in history, tested positive for drostanolone and androsterone metabolites in January 2015 [6]. Silva attributed the findings to a contaminated supplement. He received a one-year suspension from the Nevada Athletic Commission.

Silva's case differs from Rodriguez's in timeline. Silva's positive test came near the end of his competitive prime, while Rodriguez's documented use spanned what should have been his peak years (ages 25 to 37).

Testosterone Use Among Non-Athlete Public Figures

The comparison becomes more complex when extending beyond competitive sports. Several prominent public figures have openly discussed testosterone therapy in contexts where no anti-doping rules apply.

Joe Rogan: Open Advocacy

Podcast host Joe Rogan has discussed his testosterone replacement therapy extensively on The Joe Rogan Experience, framing it as a quality-of-life decision for men over 40. Rogan has stated he uses testosterone along with human growth hormone (HGH) under medical supervision [8].

Rogan's openness contrasts sharply with Rodriguez's trajectory. Where Rodriguez's testosterone use was uncovered through investigation and legal proceedings, Rogan volunteered the information and has advocated for broader access to hormone optimization. This difference reflects the distinct regulatory environments: Rogan faces no competitive sanctions, while Rodriguez operated under MLB's Joint Drug Prevention and Treatment Program.

Sylvester Stallone: Age-Related HRT

Actor Sylvester Stallone was detained at Australian customs in 2007 for carrying vials of Jintropin (somatropin, a human growth hormone product) without a valid prescription. Stallone subsequently acknowledged using testosterone and HGH as part of an anti-aging regimen. He told Time magazine: "Everyone over 40 years old would be wise to investigate it because it increases the quality of your life" [9].

Stallone's case represents a third category distinct from both Rodriguez's situation and clinical hypogonadism: elective hormone optimization without a confirmed deficiency diagnosis, pursued for body composition and recovery rather than for treating documented low testosterone.

The Clinical Distinction: TRT vs. Supraphysiologic Use

Comparing these public cases requires understanding the pharmacologic difference between replacement-dose and supraphysiologic testosterone.

Replacement Dosing

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism and total testosterone consistently below 300 ng/dL (10.4 nmol/L) [7]. Standard replacement doses aim to restore serum testosterone to the mid-normal range of 450 to 600 ng/dL.

Typical prescribed regimens include testosterone cypionate 100 to 200 mg intramuscularly every 1 to 2 weeks, or testosterone gel 1% at 50 to 100 mg daily applied topically [7]. At these doses, a 2016 New England Journal of Medicine trial (the Testosterone Trials, N=790 men aged 65 and older with testosterone <275 ng/dL) showed improvements in sexual function, walking distance, and mood over 12 months with a generally favorable safety profile [10].

Supraphysiologic Use

Performance-enhancing protocols typically involve testosterone doses 2 to 10 times higher than replacement levels. A classic study by Bhasin et al. (1996, N=43) demonstrated that 600 mg of testosterone enanthate weekly (roughly 3 to 6 times the replacement dose) increased fat-free mass by 6.1 kg over 10 weeks in healthy men, even without exercise [11]. Combined with resistance training, the gain reached 9.3 kg.

Rodriguez's reported protocol during the Biogenesis period included testosterone cream and "troches" (lozenges), along with other substances such as IGF-1 and hCG [3]. The exact doses were not made public through arbitration proceedings, but the multi-agent approach strongly suggests intent to exceed physiologic replacement.

Cardiovascular Risk at Different Dose Ranges

The TRAVERSE trial (N=5,204 men aged 45 to 80 with hypogonadism and cardiovascular risk factors), published in the New England Journal of Medicine in 2023, found that testosterone replacement at standard doses did not increase the incidence of major adverse cardiovascular events compared to placebo over a median follow-up of 33 months (hazard ratio 0.99; 95% CI, 0.81 to 1.21) [12]. This finding applies specifically to replacement dosing in the studied population.

Supraphysiologic doses carry a different risk calculus. A 2017 systematic review in Annals of Internal Medicine identified dose-dependent increases in erythrocytosis (hematocrit above 54%), which raises venous thromboembolism risk [13]. Dr. Shalender Bhasin, a professor of medicine at Harvard Medical School and lead investigator of several major testosterone trials, has stated: "The risks associated with testosterone at replacement doses are categorically different from those at the supraphysiologic doses used for performance enhancement" [11].

Public Disclosure Patterns: A Framework

Examining how public figures handle testosterone disclosure reveals distinct patterns that track with the regulatory and social consequences they face.

Involuntary Disclosure Under Sanction

Rodriguez, Ramirez, and Silva all had their testosterone or PED use revealed through testing, investigation, or legal proceedings. None volunteered the information before exposure. In Rodriguez's case, disclosure came in stages: a partial admission in 2009 followed by the more comprehensive Biogenesis revelations in 2013.

This pattern is common in professional sports, where the Joint Drug Prevention and Treatment Program (MLB), UFC Anti-Doping Policy (administered by Drug Free Sport International as of 2024), and similar frameworks create binary consequences for positive findings [2].

Voluntary Disclosure Without Stigma

Rogan, Stallone, and a growing number of non-athlete public figures discuss testosterone use without facing professional penalties. The social dynamics differ substantially. A 2023 survey published in JAMA Network Open found that testosterone prescriptions among U.S. Men aged 19 to 39 increased by 52% from 2016 to 2021, suggesting growing normalization of testosterone therapy outside of sports [14].

The Hypogonadism Question

One variable that separates these cases is whether a documented testosterone deficiency preceded treatment. The AUA/Endocrine Society diagnostic threshold requires two morning serum total testosterone measurements below 300 ng/dL along with signs or symptoms such as decreased libido, erectile dysfunction, fatigue, or loss of muscle mass [7].

Rodriguez has not publicly disclosed pre-treatment testosterone levels. Neither have most athlete PED cases. In contrast, clinical TRT patients treated through telehealth platforms and endocrinology practices typically have documented lab values confirming hypogonadism before treatment initiation. This diagnostic step is what separates medically indicated TRT from elective performance enhancement.

What Rodriguez's Case Means for TRT Today

The Rodriguez saga shaped public perception of testosterone therapy in ways that persist more than a decade later. His name became shorthand for PED abuse, which complicated the medical community's efforts to normalize treatment for genuine hypogonadism.

Stigma and Access

A 2015 study in the Journal of Clinical Endocrinology and Metabolism found that negative media coverage of testosterone therapy (including sports scandals) correlated with a 15.8% decline in new testosterone prescriptions between Q4 2013 and Q4 2014 [15]. Men with confirmed low testosterone may have delayed or avoided treatment due to associations with cheating in sports.

The Evolving Standard

Current clinical practice has moved toward clearer diagnostic criteria and monitoring protocols. The Endocrine Society recommends checking hematocrit at 3 to 6 months after starting TRT and annually thereafter, with dose adjustment or phlebotomy if hematocrit exceeds 54% [7]. PSA monitoring, lipid panels, and bone density assessments round out the standard follow-up.

Rodriguez's case, viewed through a clinical lens, represents the consequences of unsupervised, supraphysiologic testosterone use obtained outside legitimate medical channels. It is not representative of monitored TRT prescribed for documented hypogonadism at physiologic replacement doses.

Men considering testosterone therapy should obtain two morning total testosterone measurements, confirm symptoms consistent with hypogonadism, and work with a qualified clinician who follows Endocrine Society guidelines for initiation, dosing, and ongoing monitoring [7].